<VariationArchive VariationID="2628103" VariationName="NM_003482.4(KMT2D):c.6782dup (p.Gly2262fs)" VariationType="Duplication" Accession="VCV002628103" Version="1" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-07-07" DateCreated="2023-11-20" MostRecentSubmission="2023-11-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2795609" VariationID="2628103">
      <GeneList>
        <Gene Symbol="KMT2D" FullName="lysine methyltransferase 2D" GeneID="8085" HGNC_ID="HGNC:7133" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>12q13.12</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="49018978" stop="49060794" display_start="49018978" display_stop="49060794" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="49412757" stop="49449106" display_start="49412757" display_stop="49449106" Strand="-" />
          </Location>
          <OMIM>602113</OMIM>
          <Haploinsufficiency last_evaluated="2020-01-23" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=KMT2D">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-01-23" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=KMT2D">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_003482.4(KMT2D):c.6782dup (p.Gly2262fs)</Name>
      <CanonicalSPDI>NC_000012.12:49040987:GGG:GGGG</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>12q13.12</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="49040987" stop="49040988" display_start="49040987" display_stop="49040988" variantLength="1" positionVCF="49040987" referenceAlleleVCF="A" alternateAlleleVCF="AG" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="49434770" stop="49434771" display_start="49434770" display_stop="49434771" variantLength="1" positionVCF="49434770" referenceAlleleVCF="A" alternateAlleleVCF="AG" />
      </Location>
      <OtherNameList>
        <Name>p.Gly2262Trpfs*37</Name>
      </OtherNameList>
      <ProteinChange>G2262fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000012.11" sequenceAccession="NC_000012" sequenceVersion="11" change="g.49434773dup" Assembly="GRCh37">
            <Expression>NC_000012.11:g.49434773dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000012.12" sequenceAccession="NC_000012" sequenceVersion="12" change="g.49040990dup" Assembly="GRCh38">
            <Expression>NC_000012.12:g.49040990dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_027827.1" sequenceAccession="NG_027827" sequenceVersion="1" change="g.19337dup">
            <Expression>NG_027827.1:g.19337dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_003482.4" sequenceAccession="NM_003482" sequenceVersion="4" change="c.6782dup" MANESelect="true">
            <Expression>NM_003482.4:c.6782dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_003473.3" sequenceAccession="NP_003473" sequenceVersion="3" change="p.Gly2262fs">
            <Expression>NP_003473.3:p.Gly2262fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_003482.3" sequenceAccession="NM_003482" sequenceVersion="3" change="c.6782dup">
            <Expression>NM_003482.3:c.6782dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_003482.4(KMT2D):c.6782dup (p.Gly2262fs) AND Kabuki syndrome 1" Accession="RCV003391173" Version="2">
        <ClassifiedConditionList TraitSetID="2049">
          <ClassifiedCondition DB="MedGen" ID="CN030661">Kabuki syndrome 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2021-03-09" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-03-09" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-11-20" MostRecentSubmission="2023-11-20">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="2049" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1879" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Kabuki syndrome 1</ElementValue>
                <XRef ID="MONDO:0007843" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">KABUK1</ElementValue>
                <XRef Type="MIM" ID="147920" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Kabuki syndrome (KS) is characterized by typical facial features (long palpebral fissures with eversion of the lateral third of the lower eyelid; arched and broad eyebrows; short columella with depressed nasal tip; large, prominent, or cupped ears), minor skeletal anomalies, persistence of fetal fingertip pads, mild-to-moderate intellectual disability, and postnatal growth deficiency. Other findings may include: congenital heart defects, genitourinary anomalies, cleft lip and/or palate, gastrointestinal anomalies including anal atresia, ptosis and strabismus, and widely spaced teeth and hypodontia. Functional differences can include: increased susceptibility to infections and autoimmune disorders, seizures, endocrinologic abnormalities (including isolated premature thelarche in females), feeding problems, and hearing loss.</Attribute>
                <XRef ID="NBK62111" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">21882399</ID>
                <ID Source="BookShelf">NBK62111</ID>
              </Citation>
              <XRef ID="2322" DB="Orphanet" />
              <XRef ID="CN030661" DB="MedGen" />
              <XRef ID="MONDO:0007843" DB="MONDO" />
              <XRef Type="MIM" ID="147920" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="7681841" SubmissionDate="2023-11-13" DateLastUpdated="2023-11-20" DateCreated="2023-11-20">
        <ClinVarSubmissionID localKey="SUB13970251" submittedAssembly="GRCh37" title="SUB13970251" />
        <ClinVarAccession Accession="SCV004101782" DateUpdated="2023-11-20" DateCreated="2023-11-20" Type="SCV" Version="1" SubmitterName="Clinical Genomics Laboratory, Stanford Medicine" OrgID="507411" OrganizationCategory="laboratory" OrgAbbreviation="CGP" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-03-09">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The p.Gly2262Trpfs*37 variant in the KMT2D gene was identified de novo in this individual, but has not been previously reported in association with disease. This variant was absent from large population databases, including the Genome Aggregation Database (http://gnomad.broadinstitute.org/). The p.Gly2262Trpfs*37 variant results in a 1 bp insertion in exon 31/54, which causes a shift in the protein reading frame, leading to a premature termination codon 37 amino acids downstream. Heterozygous loss of function is an established mechanism of disease for the KMT2D gene. These data were assessed using the ACMG/AMP variant interpretation guidelines. In summary, there is sufficient evidence to classify the p.Gly2262Trpfs*37 variant as pathogenic for autosomal dominant Kabuki syndrome based on the information above. [ACMG evidence codes used: PVS1; PS2_Moderate; PM2]</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="SingleHeterozygote" integerValue="1" />
            </ObservedData>
            <Comment>Heterozygous (de novo)</Comment>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="KMT2D">
              <Name>lysine methyltransferase 2D</Name>
            </Gene>
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>p.Gly2262Trpfs*37</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_003482.3:c.6782dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="147920" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13970251</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7681841" TraitType="Disease" MappingType="XRef" MappingValue="147920" MappingRef="OMIM">
        <MedGen CUI="CN030661" Name="Kabuki syndrome 1" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

